AU2010295445B2 - Role of N-2 hydroxy-ethyl-piperazine-N'-2-ethane sulfonic acid (HEPES) in pain control and reversal of demyelinization injury - Google Patents

Role of N-2 hydroxy-ethyl-piperazine-N'-2-ethane sulfonic acid (HEPES) in pain control and reversal of demyelinization injury Download PDF

Info

Publication number
AU2010295445B2
AU2010295445B2 AU2010295445A AU2010295445A AU2010295445B2 AU 2010295445 B2 AU2010295445 B2 AU 2010295445B2 AU 2010295445 A AU2010295445 A AU 2010295445A AU 2010295445 A AU2010295445 A AU 2010295445A AU 2010295445 B2 AU2010295445 B2 AU 2010295445B2
Authority
AU
Australia
Prior art keywords
composition
hepes
cancer
dissolved
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010295445A
Other languages
English (en)
Other versions
AU2010295445A1 (en
Inventor
Ivan E. Danhof
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bespoke Bioscience LLC
Original Assignee
Bespoke Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bespoke Bioscience LLC filed Critical Bespoke Bioscience LLC
Publication of AU2010295445A1 publication Critical patent/AU2010295445A1/en
Priority to AU2014206220A priority Critical patent/AU2014206220B2/en
Application granted granted Critical
Publication of AU2010295445B2 publication Critical patent/AU2010295445B2/en
Assigned to BESPOKE BIOSCIENCE, LLC reassignment BESPOKE BIOSCIENCE, LLC Request for Assignment Assignors: NORTH TEXAS MEDICAL ASSOCIATES
Priority to AU2016228315A priority patent/AU2016228315B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010295445A 2009-09-17 2010-09-17 Role of N-2 hydroxy-ethyl-piperazine-N'-2-ethane sulfonic acid (HEPES) in pain control and reversal of demyelinization injury Active AU2010295445B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2014206220A AU2014206220B2 (en) 2009-09-17 2014-07-28 Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
AU2016228315A AU2016228315B2 (en) 2009-09-17 2016-09-19 Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24346409P 2009-09-17 2009-09-17
US61/243,464 2009-09-17
PCT/US2010/049405 WO2011035212A2 (en) 2009-09-17 2010-09-17 Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014206220A Division AU2014206220B2 (en) 2009-09-17 2014-07-28 Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury

Publications (2)

Publication Number Publication Date
AU2010295445A1 AU2010295445A1 (en) 2012-04-12
AU2010295445B2 true AU2010295445B2 (en) 2014-09-25

Family

ID=43757159

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010295445A Active AU2010295445B2 (en) 2009-09-17 2010-09-17 Role of N-2 hydroxy-ethyl-piperazine-N'-2-ethane sulfonic acid (HEPES) in pain control and reversal of demyelinization injury

Country Status (18)

Country Link
US (4) US8883855B2 (enExample)
EP (3) EP2477626A4 (enExample)
JP (4) JP2013505264A (enExample)
KR (1) KR101737775B1 (enExample)
CN (4) CN107260740A (enExample)
AR (1) AR078290A1 (enExample)
AU (1) AU2010295445B2 (enExample)
BR (1) BR112012006155A2 (enExample)
CA (3) CA3122553A1 (enExample)
HK (1) HK1199621A1 (enExample)
IL (2) IL264055B2 (enExample)
IN (1) IN2012DN02499A (enExample)
MX (2) MX360190B (enExample)
MY (2) MY174012A (enExample)
NZ (1) NZ598861A (enExample)
SG (3) SG179191A1 (enExample)
TW (2) TWI494106B (enExample)
WO (1) WO2011035212A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10213425B2 (en) 2009-09-17 2019-02-26 Bespoke Bioscience, Llc Role of N-2-hydroxy-ethyl-piperazine-N′-2-ethane sulfonic acid (HEPES) in pain control and reversal of demyelinization injury

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2956919C (en) 2014-07-21 2022-07-19 Glia, Llc Method for treating radiotherapy- and chemotherapy-associated cognitive or emotional impairment with cannabinoids
CA2984379C (en) * 2015-04-28 2024-06-11 Newsouth Innovations Pty Limited Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies, and inactivity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728375A (en) * 1993-03-29 1998-03-17 Queen's University At Kingston Method for treating amyloidosis
US6071919A (en) * 1996-02-13 2000-06-06 T. Ronald Theodore Zwitterionic compositions and methods as biological response modifiers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU641529B2 (en) * 1990-07-30 1993-09-23 Bloomfield D.A. Zwitterionic compounds and their N-halo derivatives for use in the treatment of clinical conditions
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
WO1997002270A1 (de) 1995-07-06 1997-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Thiolsilane, verfahren zu deren herstellung und deren verwendung
NZ550199A (en) * 1998-02-11 2008-07-31 Bellus Health Int Ltd Treatment of inflammation, abeta-induced cell toxicity, neuronal cell death or neuronal cell loss in subjects suffering from alzheimer's disease
US9044478B2 (en) 2004-11-10 2015-06-02 Institut National De La Sante Et De La Recherche Medicale Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases
JP2010532331A (ja) * 2007-07-05 2010-10-07 アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 抗痙攣医薬組成物
EP2011491A1 (en) 2007-07-05 2009-01-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticonvulsive pharmaceutical compositions
EP2163246A1 (en) * 2008-09-12 2010-03-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Taurine or taurine-like substances for the prevention of the irreversible visual effects of vigabatrin
US8709299B2 (en) 2009-09-04 2014-04-29 Basf Se Dye sensitised solar cell
AU2014206220B2 (en) 2009-09-17 2016-09-29 Bespoke Bioscience, Llc Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
MY174012A (en) 2009-09-17 2020-03-03 Bespoke Bioscience Llc Role of n-2-hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728375A (en) * 1993-03-29 1998-03-17 Queen's University At Kingston Method for treating amyloidosis
US6071919A (en) * 1996-02-13 2000-06-06 T. Ronald Theodore Zwitterionic compositions and methods as biological response modifiers

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10213425B2 (en) 2009-09-17 2019-02-26 Bespoke Bioscience, Llc Role of N-2-hydroxy-ethyl-piperazine-N′-2-ethane sulfonic acid (HEPES) in pain control and reversal of demyelinization injury

Also Published As

Publication number Publication date
IN2012DN02499A (enExample) 2015-08-28
US9867820B2 (en) 2018-01-16
US20190142825A1 (en) 2019-05-16
MX360190B (es) 2018-10-24
JP6347807B2 (ja) 2018-06-27
CA3122553A1 (en) 2011-03-24
SG10201500510YA (en) 2015-03-30
HK1199621A1 (en) 2015-07-10
KR101737775B1 (ko) 2017-05-19
EP2835133B1 (en) 2019-04-24
CA2774375C (en) 2018-02-13
CA2977918A1 (en) 2011-03-24
EP2477626A2 (en) 2012-07-25
JP2013505264A (ja) 2013-02-14
EP3520794A3 (en) 2019-11-20
TWI494106B (zh) 2015-08-01
EP2477626A4 (en) 2013-05-22
IL264055B1 (en) 2024-05-01
JP2015052006A (ja) 2015-03-19
CA2774375A1 (en) 2011-03-24
MY159626A (en) 2017-01-13
SG179191A1 (en) 2012-04-27
SG10202100421XA (en) 2021-02-25
CN103977405A (zh) 2014-08-13
MX2012003212A (es) 2012-09-07
CN107260740A (zh) 2017-10-20
CA2977918C (en) 2021-08-10
JP2015129150A (ja) 2015-07-16
AR078290A1 (es) 2011-10-26
WO2011035212A2 (en) 2011-03-24
EP2835133A1 (en) 2015-02-11
NZ598861A (en) 2013-01-25
IL218677A0 (en) 2012-05-31
US8883855B2 (en) 2014-11-11
CN102612366A (zh) 2012-07-25
JP5974062B2 (ja) 2016-08-23
TWI562777B (en) 2016-12-21
US20140378467A1 (en) 2014-12-25
IL264055B2 (en) 2024-09-01
CN109224077A (zh) 2019-01-18
KR20120081151A (ko) 2012-07-18
US20180028530A1 (en) 2018-02-01
EP3520794A2 (en) 2019-08-07
JP2016216493A (ja) 2016-12-22
US20110071157A1 (en) 2011-03-24
TW201440769A (zh) 2014-11-01
BR112012006155A2 (pt) 2016-06-28
IL218677B (en) 2019-01-31
US10213425B2 (en) 2019-02-26
MY174012A (en) 2020-03-03
WO2011035212A3 (en) 2011-07-14
TW201117813A (en) 2011-06-01
IL264055A (en) 2019-01-31
AU2010295445A1 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
Francis et al. Evaluation and rehabilitation of patients with adult motor neuron disease
US10213425B2 (en) Role of N-2-hydroxy-ethyl-piperazine-N′-2-ethane sulfonic acid (HEPES) in pain control and reversal of demyelinization injury
AU2016228315B2 (en) Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
AU2014206220B2 (en) Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
Cole et al. Physostigmine reversal of dysarthria and delirium after iatrogenic atropine overdose from a dental procedure
HK1244206A1 (en) Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
HK1173365A (en) Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
HK40118245A (en) Use of riluzole prodrugs to treat ataxias
Kojima et al. Treatment with L‐DOPA in Two Cases of Organic Brain Syndrome
WO2009011560A1 (es) Composición farmacéutica que comprende la combinación de risperidone y donepezilo, y su uso en el tratamiento de trastornos psicóticos, como la esquizofrenia y demencias de tipo alzheimer
Edwards et al. Parkinson's Disease and Other Movemen t Disorders (Oxford Specialist Handbooks)

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: BESPOKE BIOSCIENCE, LLC

Free format text: FORMER APPLICANT(S): NORTH TEXAS MEDICAL ASSOCIATES

FGA Letters patent sealed or granted (standard patent)